Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06234137
Status:
RECRUITING
Last Update Posted:
2024-01-31
First Post:
2024-01-23
Brief Title:
A Prospective Open Multicenter Single-arm Clinical Studie of Docetaxel Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Sponsor:
Wang Ouchen
Organization:
First Affiliated Hospital of Wenzhou Medical University
Study Overview
Official Title:
A Prospective Open Multicenter Single-arm Clinical Studie of Docetaxel Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
neoPICD
Brief Summary:
This study is a prospective open multi-center single arm trial The treatment group will receive six cycles of docetaxel carboplatin combined with Inetetamab and Pyrotinib before surgery By focusing on tpCR ypT0is ypN0 evaluated by pathology the efficacy of docetaxel carboplatin combined with Inetetamab and Pyrotinib in the preoperative treatment of locally advanced HER2-positive breast cancer will be evaluated During long-term follow-up event-free survival EFS disease-free survival DFS distant metastasis-free survival DDFS overall survival OS central nervous system disease-free survival CNSDFS under this treatment regimen will be evaluated and the efficacy-related biomarkers will be explored The cardiotoxicity of Inetetamab and Pyrotinib in the treatment of breast cancer is also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None